176 related articles for article (PubMed ID: 37860686)
1. Synthesis of novel spirochromane incorporating Schiff's bases, potential antiproliferative activity, and dual EGFR/HER2 inhibition: Cell cycle analysis and
Othman DIA; Hamdi A; Elhusseiny WM; El-Azab AS; Bakheit AH; Hefnawy M; Abdel-Aziz AA
Saudi Pharm J; 2023 Nov; 31(11):101803. PubMed ID: 37860686
[TBL] [Abstract][Full Text] [Related]
2. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
3. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
4. Bio-Oriented Synthesis of Novel (S)-Flurbiprofen Clubbed Hydrazone Schiff's Bases for Diabetic Management: In Vitro and In Silico Studies.
Alam A; Ali M; Rehman NU; Ullah S; Halim SA; Latif A; Zainab ; Khan A; Ullah O; Ahmad S; Al-Harrasi A; Ahmad M
Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745591
[TBL] [Abstract][Full Text] [Related]
5. Antiglycation Activity of Triazole Schiff's Bases Against Fructosemediated Glycation: In Vitro and In Silico Study.
Shaikh M; Siddiqui S; Zafar H; Naqeeb U; Subzwari F; Imad R; Khan KM; Choudhary MI
Med Chem; 2020; 16(4):575-591. PubMed ID: 30747076
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors.
Ibrahim TS; Malebari AM; Mohamed MFA
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832959
[TBL] [Abstract][Full Text] [Related]
7. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
Halim PA; Sharkawi SMZ; Labib MB
Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis,
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
[TBL] [Abstract][Full Text] [Related]
9. Schiff's base derivatives bearing nitroimidazole moiety: new class of antibacterial, anticancer agents and potential EGFR tyrosine kinase inhibitors.
Makawana JA; Sun J; Zhu HL
Bioorg Med Chem Lett; 2013 Dec; 23(23):6264-8. PubMed ID: 24144854
[TBL] [Abstract][Full Text] [Related]
10. An efficient sonochemical synthesis of novel Schiff's bases, thiazolidine, and pyrazolidine incorporating 1,8-naphthyridine moiety and their cytotoxic activity against HePG2 cell lines.
Ahmed NS; Alfooty KO; Khalifah SS
ScientificWorldJournal; 2014; 2014():587059. PubMed ID: 24723815
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
Ammar YA; Sh El-Sharief AM; Belal A; Abbas SY; Mohamed YA; Mehany ABM; Ragab A
Eur J Med Chem; 2018 Aug; 156():918-932. PubMed ID: 30096580
[TBL] [Abstract][Full Text] [Related]
12. New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: design, synthesis, biological evaluation, and computational studies.
Alamshany ZM; Algamdi EM; Othman IMM; Anwar MM; Nossier ES
RSC Adv; 2023 Apr; 13(19):12889-12905. PubMed ID: 37114032
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action.
Mohamed FAM; Alakilli SYM; El Azab EF; Baawad FAM; Shaaban EIA; Alrub HA; Hendawy O; Gomaa HAM; Bakr AG; Abdelrahman MH; Trembleau L; Mohammed AF; Youssif BGM
RSC Med Chem; 2023 Apr; 14(4):734-744. PubMed ID: 37122549
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel pyrimido[4,5-b]quinolines as potential anticancer agents and HER2 inhibitors.
Ibrahim NSM; Kadry HH; Zaher AF; Mohamed KO
Chem Biol Drug Des; 2023 Nov; 102(5):996-1013. PubMed ID: 37527951
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
El-Azab AS; Abdel-Aziz AA; AlSaif NA; Alkahtani HM; Alanazi MM; Obaidullah AJ; Eskandrani RO; Alharbi A
Bioorg Chem; 2020 Nov; 104():104345. PubMed ID: 33142413
[TBL] [Abstract][Full Text] [Related]
16. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract][Full Text] [Related]
17. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
18. In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases.
Almalki FA; Abdalla AN; Shawky AM; El Hassab MA; Gouda AM
Molecules; 2021 Jun; 26(13):. PubMed ID: 34209011
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
